Committee to reform drug regulatory system to table report in a month

Maitri Porecha New Delhi | Updated on May 22, 2020 Published on May 22, 2020

With a view to reform the drug regulatory system, the Ministry of Health and Family Welfare (MoHFW) has constituted a committee, comprising senior health officials, scientists and representatives of the pharmaceutical industry. The committee, instituted on May 11, has met on May 19 and on May 22. It is slated to submit a report on it’s findings in about a month, MoHFW sources said.

“The issue of reforms in the drug regulatory system has been engaging the attention of the Government of India for quite some time now. Although requisite procedural changes have been carried out during the current Covid-19 pandemic and have worked quite well, it is felt that comprehensive changes in the drug regulatory regime should be carried out to reflect global best practices as well as domestic requirements and to streamline the Central Drugs Standard Control Organisation to make it more effective,” the MoHFW order said.

There has been a long pending demand to bring the CDSCO, also referred to as Drug Controller General of India (DCGI), under Department of Pharmaceuticals (DoP). However a senior DoP official told Businessline, “These are mere speculations at this stage. DoP, however, does want to be an umbrella body to bring together CDSCO under MoHFW, Pharmaceutical Export Promotion Council under Ministry of Commerce and Industry as well as the National Pharmaceutical Pricing Authority, which is under DoP. But how this arrangement will work out is not clear yet.”

Sources said the committee comprises 11 members — PD Vaghela, Secretary, DoP, or a nominated representative on his behalf; Balram Bhargav, Director-General of Indian Council of Medical Research, or a nominated representative; Sanjay Kumar Rai, Professor of Community Medicine at All India Institute of Medical Sciences; Pankaj Patel, Chairman of Cadila Healthcare for Indian Pharmaceutical Association; Adar C Poonawalla, CEO, Serum Institute of India and President, Indian Vaccine Manufacturers’ Association; Eswara Reddy, Joint Drug Controller, CDSCO, two scientists from the Department of Biotechnology, and one representative from Indian Pharmacopoeia Commission. It is headed by Rajesh Bhushan, currently Officer on Special Duty at MoHFW, and who is tipped to take over as Health Secretary from Preeti Sudan in a few months.

The committee will examine earlier reports of a Parliamentary standing committee, Professor RR Choudhary Committee on clinical trials and SN Mishra Committee on qualification of DCGI, the order said.

It further said: “While nominating a member, ministries, departments and institutions should keep in mind that the officer being nominated should have a flexible approach and willing to consider far reaching reforms with open mind.”

However, civil society members pointed out that having prominent pharmaceutical industry members sitting on a government committee that is looking at reforming drug regulatory regime is problematic.

Published on May 22, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.